Human SU-DHL-5 and TMD-8 B-lymphome cell line subclones
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB14876 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Genetic heterogeneity though common in tumors has been rarely documented in cell lines. To examine how often B-lymphoma cell lines are comprised of subclones, we performed immunoglobulin (Ig) heavy chain hypermutation analysis. Revealing that subclones are not rare in B-cell lymphoma cell lines, 6/49 Ig hypermutated cell lines (12%) consisted of subclones with individual Ig mutations. Subclones were also identified in 2/284 leukemia/lymphoma cell lines exhibiting bimodal CD marker expression. We successfully isolated 10 subclones from four cell lines HG3, SU-DHL-5, TMD-8, U-2932). Whole exome sequencing was performed to molecularly characterize these subclones. We in detail describe the clonal structure of cell line HG3, derived from chronic lymphocytic leukemia. HG3 consists of three lineages each bearing clone-specific aberrations, gene expression and DNA methylation patterns. While donor patient leukemic cells were CD5+, two of three HG3 subclones had independently lost this marker. CD5 on HG3 cells was regulated by epigenetic/transcriptional mechanisms rather than by alternative splicing as reported hitherto. In conclusion, we show that the presence of subclones in cell lines carrying individual mutations and characterized by sets of differentially expressed genes is not uncommon. We show also that these subclones can be useful isogenic models for regulatory and functional studies.
2016-09-30 | E-MTAB-4956 | biostudies-arrayexpress
Project description:SU-DHL-5 cells display limited expression of the SUMO isopeptidase SENP6. In this experiment, the chromatin associated fraction of SU-DHL-5 cells was analysed by mass spectrometry. SU-DHL-5 cells were either stably transfected with an empty vector or with a SENP6 expression construct. Changes in protein levels were compared between these two cell lines in triplicate experiments.
2022-02-17 | PXD027355 | Pride
Project description:Genetic heterogeneity though common in tumors has been rarely documented in cell lines. To examine how often B-lymphoma cell lines are comprised of subclones, we performed immunoglobulin (Ig) heavy chain hypermutation analysis. Revealing that subclones are not rare in B-cell lymphoma cell lines, 6/49 Ig hypermutated cell lines (12%) consisted of subclones with individual Ig mutations. Subclones were also identified in 2/284 leukemia/lymphoma cell lines exhibiting bimodal CD marker expression. We successfully isolated 10 subclones from four cell lines HG3, SU-DHL-5, TMD-8, U-2932). Whole exome sequencing was performed to molecularly characterize these subclones. We in detail describe the clonal structure of cell line HG3, derived from chronic lymphocytic leukemia. HG3 consists of three lineages each bearing clone-specific aberrations, gene expression and DNA methylation patterns. While donor patient leukemic cells were CD5+ , two of three HG3 subclones had independently lost this marker. CD5 on HG3 cells was regulated by epigenetic/transcriptional mechanisms rather than by alternative splicing as reported hitherto. In conclusion, we show that the presence of subclones in cell lines carrying individual mutations and characterized by sets of differentially expressed genes is not uncommon. We show also that these subclones can be useful isogenic models for regulatory and functional studies.
2016-09-30 | E-MTAB-4955 | biostudies-arrayexpress
Project description:To further figure out the molecular mechanisms of IL-17A-mediated DLBCL cells growth, we used the Whole Human Genome Oligo Microarray (4×44K, Agilent Technologies) to identify genes expression. Six samples of SU-DHL-2 cells (2×10^6 cells/ml) co-cultured with or without IL-17A (200pg/ml) for 72hr in vivo. Three samples of SU-DHL-2 cells were all co-cultured with IL-17A , other three samples of SU-DHL-2 cells without IL-17A treatment were used as controls. Then, all these six samples of SU-DHL-2 cells were measured by microarray.
2018-06-16 | GSE115855 | GEO
Project description:RAD21 ChIA-PET in human SU-DHL-4 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf
2019-03-03 | GSE127039 | GEO
Project description:RAD21 ChIA-PET in human SU-DHL-2 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf
2019-03-03 | GSE127019 | GEO
Project description:To understand the mechanisms of CBL0137 in B-NHL therapy, gene expression changes of SU-DHL-4, Raji and Jeko cell lines after CBL0137 treatment were analyzed by RNA-seq
2023-02-07 | GSE208679 | GEO
Project description:Genes expression of SU-DHL-2 cells treated with IL-17A
| PRJNA476315 | ENA
Project description:We generated gemcitabine resistant subclones from the human pancreatic cancer cell line BxPC3 using chronic low dose exposure to gemcitabine. Three gemcitabine resistant subclones (BxGR-80C, BxGR-120C and BxGR-360C) were sequenced in addition to BxPC3 cells.
2021-12-21 | E-MTAB-11186 | biostudies-arrayexpress
Project description:PAR-CLIP was performed on the Argonaute-2 protein (AGO2) in four lymphoma cell lines:
Namalwa
Raji
SU-DHL-4
SU-DHL-6
| EGAD00001001468 | EGA